Lupus Science & Medicine

1. Lupus Sci Med17 Jun 2026

   Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus

   Research articleLupus & APS

2. Lupus Sci Med17 Jun 2026

   Mental health monitoring in adolescents with SLE: associations with lupus low disease activity state and remission

   Cohort studyPediatric

3. Lupus Sci Med17 Jun 2026

   Belimumab induces early and sustained resolution of lupus thrombocytopenia

   Meta-analysisLupus & APS

4. Lupus Sci Med16 Jun 2026

   Stage-resolved mapping of RP105 (CD180)-negative B cells reveals residual plasmablast-lineage skewing in SLE: a cross-sectional study

   Cross-sectional studyLupus & APS

5. Lupus Sci Med12 Jun 2026

   Systemic Lupus International Collaborating Clinics Frailty Index predicts mortality in systemic lupus erythematosus patients: data from the Almenara Lupus Cohort

   Cohort studyLupus & APS

6. Lupus Sci Med2 Jun 2026

   Epidemiology changes in systemic lupus erythematosus in Italy: the EASIEST study

   Cross-sectional studyLupus & APS

7. Lupus Sci Med29 May 2026

   Clinical utility of a multianalyte lupus risk score incorporating cell-bound complement activation products: a systematic evaluation

   Diagnostic or prognostic studyLupus & APS

8. Lupus Sci Med27 May 2026

   Beyond renal response: sustained systemic disease control protects against adverse long-term outcomes in lupus nephritis

   Cohort studyLupus & APS

9. Lupus Sci Med27 May 2026

   Children exposed to hydroxychloroquine in utero show no signs of retinal toxicity at age 5

   Cross-sectional studyPediatric

10. Lupus Sci Med20 May 2026

    Comparison of aspirin and rivaroxaban for the prevention of pulmonary embolism and deep vein thrombosis in high thrombotic risk patients with systemic lupus erythematosus: study protocol for a multicentre, prospective, randomised controlled trial

    Trial designLupus & APS

11. Lupus Sci Med18 May 2026

    Comparison of BAFF and type I IFN activity in blood and placenta in SLE and healthy pregnancies

    Cohort studyLupus & APS

12. Lupus Sci Med17 May 2026

    Incidence of serious infections, herpes zoster and hepatitis B virus reactivation among patients with SLE: a cohort study using a health claims database in Japan

    Cohort studyLupus & APS

13. Lupus Sci Med7 May 2026

    Impact of an online lupus self-management programme in an established, population-based cohort of adults with diagnosed SLE: a mixed-methods study

    Research articleLupus & APS

14. Lupus Sci Med7 May 2026

    Reference intervals for aCL and anti-β2GPI IgAGM antibodies in a large health-inspection population: a foundational study for combined-isotype assay interpretation

    Cross-sectional studyLupus & APS

15. Lupus Sci Med4 May 2026

    Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort

    Cohort studyLupus & APS

16. Lupus Sci Med4 May 2026

    Controlling cardiovascular risk factors reduces progression of atherosclerosis in a multiethnic cohort of patients with lupus

    Cohort studyLupus & APS

17. Lupus Sci Med27 Apr 2026

    Evaluation of clinical, histological and biomarker response after initial therapy of lupus nephritis

    Cohort studyLupus & APS

18. Lupus Sci Med27 Apr 2026

    Forgotten costs of systemic lupus erythematosus: estimating indirect healthcare costs in a national prospective observational Canadian lupus cohort

    Cohort studyLupus & APS

19. Lupus Sci Med27 Apr 2026

    Validity and applicability of machine learning models for systemic lupus erythematosus diagnosis

    Diagnostic or prognostic studyLupus & APS

20. Lupus Sci Med22 Apr 2026

    Elevated serum brain injury markers are associated with disease activity, pro-inflammatory cytokine levels and cognitive dysfunction in adolescents with childhood-onset SLE

    Cross-sectional studyPediatric

21. Lupus Sci Med21 Apr 2026

    Serum lipidomic and metabolomic signatures link epicardial adipose tissue to cardiovascular diseases in SLE: a post-hoc analysis

    Cohort studyLupus & APS

22. Lupus Sci Med20 Apr 2026

    Baseline characteristics of patients with SLE with and without lupus nephritis from the Latin American multiethnic GLADEL 2.0 cohort

    Cross-sectional studyLupus & APS

23. Lupus Sci Med20 Apr 2026

    Adverse childhood experiences are associated with disease and mental health outcomes in childhood-onset SLE

    Cohort studyPediatric

24. Lupus Sci Med15 Apr 2026

    Real-world experience of anifrolumab treatment in patients with moderate-to-severe SLE: a retrospective study of patients in early access programmes

    Cohort studyLupus & APS

25. Lupus Sci Med10 Apr 2026

    Demographic and clinical characteristics of patients with systemic lupus erythematosus across five registries: the LupusNet federated data network

    Cross-sectional studyLupus & APS

26. Lupus Sci Med9 Apr 2026

    Human papillomavirus (HPV) seroprevalence, cervical HPV prevalence and cervical lesions in systemic lupus erythematosus (SLE) and immunocompetent women

    Cross-sectional studyLupus & APS

27. Lupus Sci Med9 Apr 2026

    Lectin pathway of complement in SLE: MAP-1 as a marker of haematological manifestations and elevated type I interferon activity

    Cross-sectional studyLupus & APS

28. Lupus Sci Med8 Apr 2026

    Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials

    Secondary analysisLupus & APS

29. Lupus Sci Med8 Apr 2026

    Conditions identified by common comprehensive geriatric assessment measures and subsequent acute care among adults with SLE

    Cohort studyLupus & APS

30. Lupus Sci Med8 Apr 2026

    Unsupervised clustering of clinical and laboratory features of systemic lupus erythematosus: insights from a multicentre cohort

    Cohort studyLupus & APS

31. Lupus Sci Med1 Apr 2026

    Comparison of Evans syndrome and isolated autoimmune cytopenias in SLE: a retrospective study

    Cohort studyLupus & APS

32. Lupus Sci Med31 Mar 2026

    Pulmonary diseases in SLE: a population-based cross-sectional study

    Cross-sectional studyLupus & APS

33. Lupus Sci Med24 Mar 2026

    ‘Getting comfortable with the uncomfortable’: barriers, facilitators and influences on reproductive health discussions from Hispanic women with systemic lupus erythematosus in the USA – a qualitative study

    Research articleLupus & APS

34. Lupus Sci Med24 Mar 2026

    Long-term outcomes of hydroxychloroquine dose reduction in Puerto Ricans with systemic lupus erythematosus: 6-year follow-up

    Cohort studyLupus & APS

35. Lupus Sci Med23 Mar 2026

    Frequency and associated factors of herpes zoster infection in SLE patients from Latin America: data from the GLADEL 2.0 cohort

    Cohort studyLupus & APS

36. Lupus Sci Med19 Mar 2026

    Risk factor of osteoporosis in systemic lupus erythematosus patients: a cross-sectional study in a tertiary hospital in Indonesia

    Cross-sectional studyOsteoporosis

37. Lupus Sci Med18 Mar 2026

    Genetic and phenotypic landscape of monogenic lupus: insights from an international cohort

    Cohort studyPediatric

38. Lupus Sci Med18 Mar 2026

    Measurement of haemolytic anaemia in a novel treatment response measure for SLE clinical trials

    Guideline or statementLupus & APS

39. Lupus Sci Med18 Mar 2026

    Twelve-month follow-up after telitacicept withdrawal in patients with SLE: a single-centre study

    Cohort studyLupus & APS

40. Lupus Sci Med13 Mar 2026

    Left Ventricular Mass Index as an independent predictor of major adverse cardiovascular and cerebrovascular events in patients with SLE

    Cohort studyLupus & APS

All 423 Briefs in ExploreShowing Briefs 81–120 of 423, newest first